This inventor holds 46 USPTO granted patents and 2 published patent applications, plus 5 CIPO patents and 5 EPO patents, primarily in Opioid Receptor Compounds. Top assignees: Research Triangle Institute, University of Arkansas, Racon Incorporated. Active years: 1983-2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Location History:
- Durham, NC (US) (1983 - 2017)
- Durham, NJ (US) (2021)
- Research Triangle Park, NC (US) (2002 - 2022)
Company Filing History:
39 out of 359 
5 out of 851 
2 out of 3 
Years Active: 1983-2022
Areas of Expertise:
Title: **Frank Ivy Carroll: Innovations in Pharmacotherapy**
Introduction
Frank Ivy Carroll, a prolific inventor based in Durham, NC, has made significant contributions to the field of pharmacotherapy, holding an impressive 46 patents throughout his career. His work focuses on developing compounds aimed at treating various mental health disorders and addictions, showcasing a commitment to improving the lives of those affected by these issues.
Latest Patents
Among his latest innovations, Carroll has developed substituted 1,2,3,4-tetrahydroisoquinolines, which act as kappa opioid antagonists. These compounds are noted for their potential as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addictions to substances such as cocaine, methamphetamine, nicotine, alcohol, and opiates. This patent underscores the importance of selective kappa opioid receptor antagonist compounds and their pharmaceutical applications in addressing critical mental health challenges.
Additionally, Carroll’s invention of monoamine reuptake inhibitors presents bupropion analogue compounds designed to inhibit the reuptake of various monoamines. These compounds selectively bind to monoamine transporters, including those for dopamine, norepinephrine, and serotonin. The implications of this research are significant, as these compounds may be utilized in treating conditions responsive to monoamine reuptake inhibition, including addiction, depression, and obesity.
Career Highlights
Carroll's career has been marked by his affiliation with esteemed research institutions such as the Research Triangle Institute and the University of Arkansas. His contributions to research in pharmacotherapy are recognized within the scientific community and underscore the impact of his inventions on modern medicine.
Collaborations
Throughout his journey, Carroll has collaborated with notable professionals in the field, including Philip Abraham and Anita H. Lewin. These partnerships have further advanced the research and development of his innovative compounds, allowing for deeper exploration of their therapeutic potential.
Conclusion
Frank Ivy Carroll’s impressive portfolio of patents reflects his dedication to addressing complex health issues through innovative pharmacological research. His continued work in the field promises to contribute further to the advancement of effective treatments for mental health disorders and addictions, signifying a lasting impact on both the scientific community and the lives of patients.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile